Skip to content

TuHURA Biosciences, Inc. HURA Proceeds From Warrant Exercises

Proceeds From Warrant Exercises at other companies

ImmunityBio, Inc. logo
ImmunityBio, Inc.IBRX
$53.54M
Avalo Therapeutics logo
Avalo TherapeuticsAVTX
$0-100%

Other financials

Income statement

See full
Revenue-
Net income-$7.5M-13.1%
EPS (diluted)-$0.13+13.3%

Balance sheet

See full
Cash & equivalents$6.3M+1.3%
Total debt$456.9K+178%
Total equity$23.2M+135%
Total assets$29.7M+103%

Cash flow

See full
Operating cash flow-$4.4M+6.9%
CapEx$48.8K+14.5%
Free cash flow-$4.5M+6.7%

Valuation

See full
Market cap$155.39M+45.8%
Enterprise value$149.54M+52.3%

Returns & leverage

See full
Return on equity-187.2%
Debt / equity0.0×
Current ratio1.2×-1.8×

Where this comes from

Reported directly by TuHURA Biosciences, Inc. in its filing.

Tagged under the XBRL concept us-gaap:ProceedsFromWarrantExercises.

The official record: TuHURA Biosciences, Inc.’s 10-Q, filed August 14, 2025, on SEC EDGAR. View the filing →

Ask your AI about TuHURA Biosciences, Inc.'s proceeds from warrant exercises.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is TuHURA Biosciences, Inc.'s proceeds from warrant exercises?
TuHURA Biosciences, Inc. (HURA) reported proceeds from warrant exercises of $3.12M in Q2 2025.
What does proceeds from warrant exercises mean?
This captures the cash proceeds received by the company when holders of warrants exercise their rights to purchase common stock at a predetermined price. It acts as a non-dilutive or secondary source of equity capital that strengthens the company's cash position.